Kairos Pharma, Ltd.

KAPA

AMEX

Healthcare

Biotechnology

Los Angeles, CA, US1 employeeskairospharma.com

$0.59

+0.01(1.97%)

Mkt Cap $12M

$0.45

$1.97

52-Week Range

At a Glance

AI-generated

Kairos Pharma, Ltd.

Revenue breakdown: Item One And Two (48.8%), Item Four (24.4%), Phase Three Clinical Trial (24.4%).

$12M

Market Cap

—

Revenue

—

Net Income

Employees1

Fundamentals

How The Business Makes Money

Revenue by Segment

Item One And Two48.8%($100M)

Item Four24.4%($50M)

Phase Three Clinical Trial24.4%($50M)

Item One Two And Three2.4%($5M)

Activity

What Changed Recently

Material Agreement

Mar 1, 2026

Entry into a Material Definitive Agreement. Binding Term Sheet On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a bind

Other Event

Feb 25, 2026

, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch

Peer Companies

Company	Price	Change	Market Cap	P/E
CINGCingulate Inc.	$6.20	+3.08%	$35M	-1.7
LEXXLexaria Bioscience Corp.	$1.04	+20.08%	$20M	-1.4
ALLRAllarity Therapeutics, In...	$1.17	+3.54%	$19M	-1.1
LIXTLixte Biotechnology Holdi...	$3.14	+2.45%	$14M	-4.0
ENTOENTO	$2.85	-5.00%	$14M	—
PTHSPelthos Therapeutics Inc.	$20.40	-4.23%	$13M	—
BCTXBriaCell Therapeutics Cor...	$4.08	-1.57%	$8M	-0.3
PULMPulmatrix, Inc.	$1.39	+5.30%	$5M	-1.6

Analyst View

Company Profile

CIK0001962011

ISINUS48301N1046

Phone310-948-2356

Address2355 Westwood Blvd., Los Angeles, CA, 90064, US

SEC EDGAR